echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > "Super pill" expected to be available within three years to treat more than 2,000 diseases

    "Super pill" expected to be available within three years to treat more than 2,000 diseases

    • Last Update: 2020-07-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    U.Sresearchers say they are developing a breakthrough new drug that could treat more than 2,000 geneticdiseases, including Duchenne muscular dystrophy and several types of cystic fibrosis
    If clinical trials go well, the drug is expected to be available within three yearsThe results were published April 23 in the British journal NatureDuxing muscular dystrophy occurs in 1 in 3,500 men, a sexually linked recessive genetic disorder and the most common muscular dystrophy inchildrenchildren with the disease, may have trouble walking before school, between the ages of 7 and 12 years, almost all patients will lose the ability to walkIn their 20s, they all died ofheartand lung muscle failureDuxing muscular dystrophy is mainly due to the patient's muscle cells do not normally produce a protein called anti-myotrophin, resulting in muscle weakness throughout the patientBecause it is a sexual lysy recessive inheritance, onlymalewill have the conditionWomen who usually have an abnormal gene does not develop the condition, but have a 50% chance of inheriting the mutated gene on their son The genetic information stored in the human body's DNA is composed of four genetic codes: adenine (A), ostrich (G), thymus (T), and cytosine (C) After RNA transcription and splicing, thymus (T) is replaced by urinary (U) When RNA translates proteins, it forms a gene reading box with three genetic codes If the genetic code is missing or duplicated, it will cause the reading box downstream of the missing segment to be completely disrupted and useless proteins synthesized If the genetic code is not missing, but a genetic code changes to form a UAA, UAG, and UGA stop code, will also make the process of translation of proteins prematurely stopped Scientists speculate that a variety of human genetic diseases, including Duchenne muscular dystrophy, caused by genetic ally-righteous mutations The team, led by Dr Sweeney of the University of Pennsylvania, selected a new drug called PTC-124, which works in a similar way to gingantimy, which prevents ribosomes from identifying incorrect stop codes and continues to synthesize functional proteins, but unlike Gingdamin, PTC-124 does not affect normal stop codes, so safety is greatly improved Experiments in mice have shown that the drug has the effect of increasing the level of anti-myotrophin and restoring muscle function Dr Sweeney said the new treatment could help treat of a variety of genetic
    diseases caused by genetically unrighteous mutations Maritta, director of the Muscular Dystrophy Society, said the findings were encouraging In the long run, the drug is expected to become a treatment for Duchenne muscular dystrophy (reprinted from Science and Technology Daily)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.